SCHEMBL17015771

SCHEMBL17015771

O=C(c1ccccc1)c1ccc(-n2c3ccccc3c3ccc4c(ccn4-c4cc(-c5ccccc5)cc(-c5ccccc5)c4)c32)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GLA P06280 1/20 0.35
PTPN1 P18031 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HDAC4 P56524 1/20 0.34
AKR1C4 P17516 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
RORC P51449 4/20 0.34
CYP19A1 P11511 1/20 0.33
HPGD P15428 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015776 0.93 CNR2 (0.36) CNR2KDM4EALDH1A1SMN1; SMN2GLA
SCHEMBL17015691 0.92 CA12 (0.38) CNR2KDM4EALDH1A1SMN1; SMN2GLA
SCHEMBL17015774 0.92 CNR2 (0.35) CNR2KDM4EALDH1A1SMN1; SMN2GLA
SCHEMBL17016174 0.89 L3MBTL1 (0.41) CNR2KDM4EALDH1A1SMN1; SMN2GLA
SCHEMBL17015222 0.89 L3MBTL1 (0.41) CNR2KDM4EALDH1A1SMN1; SMN2GLA
SCHEMBL17015784 0.89 L3MBTL1 (0.42) KDM4EALDH1A1PTPN1HDAC4AKR1C4
SCHEMBL15632270 0.89 L3MBTL1 (0.39) KDM4EALDH1A1HDAC4AKR1C4AKR1C3
SCHEMBL16613798 0.89 L3MBTL1 (0.39) KDM4EALDH1A1HDAC4AKR1C4AKR1C3
SCHEMBL16613857 0.88 L3MBTL1 (0.44) KDM4EALDH1A1HDAC4MAPTL3MBTL1
SCHEMBL17015779 0.87 CLK1 (0.36) CNR2ALDH1A1SMN1; SMN2GLARORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 CNR2 1583/4885KDM4E 1286/4885ALDH1A1 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.